Preliminary analysis of data from an ongoing investigator-initiated, single-center Phase 1 study supported by BioNTech and Genentech and conducted at Memorial Sloan Kettering Cancer Center, New York, United States. Autogene Cevumeran, a fully individualized mRNA cancer immunotherapy (iNeST) demonstrated that vaccine-induced immunity significantly correlates with delayed tumor recurrence in patients with resected pancreatic ductal adenocarcinoma.
Research by Oregon State University has uncovered a potential new therapy for pancreatic cancer, whose survival rate is among the lowest of all malignancies.
When you’re facing a pancreatic cancer diagnosis, humor may be tough to come by. Instead, feelings of grief, sadness, depression and anxiety become so all-consuming that getting a chuckle from even the most hilarious prank seems like an impossibility. But here’s the thing: It turns out that laughter — whether forced or spontaneous — is […]
Results from an ongoing phase 2b GRECO-2 clinical trial show that the novel drug GC4419 may be promising in treating patients with unresectable or borderline resectable locally advanced pancreatic cancer who are undergoing stereotactic body radiation therapy (SBRT). When given with SBRT, the drug led to statistically significant improvements over placebo plus SBRT in progression-free […]
By Ellen Zimmerman The Therapeutics-Focused Research Program will advance the understanding of the causes and progression of pancreatic cancer and will identify new potential therapies. This grant program will stimulate research to stretch the limits of our current understanding of pancreatic cancer treatment; promote collaboration; and identify novel therapeutic approaches and drug targets. Fifty proposals […]
New combination of three existing immunotherapy drugs may eliminate pancreatic tumors By Stephanie Elsea When it comes to fighting and destroying infected or diseased cells, T cells are the heroes. The body’s front line of defense, T cells are like soldiers deployed at the first sign of trouble to attack and block cancer cells. But like any hero, T cells can grow tired and lose effectiveness over time. That process is known as exhaustion. Every good military needs a general to determine […]
A new study from Queen Mary University of London has demonstrated that immune cells can be stimulated to assemble into special structures within pancreatic cancer such that, at least in a pre-clinical model, researchers can demonstrate an improvement in the efficacy of chemotherapy. The body’s immune system is a critical defence against illness such as […]
A diagnostic tool called the MasSpec Pen has been tested for the first time in pancreatic cancer patients during surgery. The device is shown to accurately identify tissues and surgical margins directly in patients and differentiate healthy and cancerous tissue from banked pancreas samples. At about 15 seconds per analysis, the method is more than […]